Wockhardth gets US FDA approval for Fosphenytoin

New Delhi, July 9 (UNI) Pharma major, Wockhardt Ltd, today said it has received US Food and Drug Administration (FDA) approval for marketing Fosphenytoin injections in the US market.

The injectible is used for treating complicated forms of epileptic seizures, where oral medicines cannot be administered and contains 50mg Phenytoin equivalents/ml.

Company's Chairman Habil Khorakiwala said, ''Fosphenytoin will be our third product to be launched on Day-1 after patent expiry. It is a very significant addition to our sterile portfolio for the US market. With six injections being marketed by us, our varied portfolio will enable us to expand our presence in the United States.'' Wockhardt currently markets twenty-two products in the US, a statement said.

UNI